Atomwise is a preclinical pharma company revolutionizing drug discovery with AI. They have invented the use of deep learning for structure-based drug discovery and are developing a pipeline of small-molecule drug candidates. Their AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. Atomwise is tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. 

We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. 

We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers

Bill & Melinda Gates Foundation

Sanabil

AME Cloud Ventures

Y Combinator

Baidu Ventures

DCVC

Dolby Family Ventures

Tencent

Colorcon

Touchdown Ventures

Atomwise is revolutionizing how drugs are discovered using #AI. Our deep learning technology for structure-based drug discovery enables our pipeline of small-molecule drug candidates. 

Learn more about Atomwise and how we’re changing traditional #drugdiscovery ⬇️

We're excited to announce the nomination of our very first AI-driven development candidate, focused on TYK2 inhibition. This marks a significant milestone in our journey to revolutionize drug discovery and development through artificial intelligence.

Joining us on this incredible venture is Dr. Neely Mozaffarian, MD, PhD, who has been appointed as our new Chief Medical Officer. With her expertise and leadership, we're poised to advance groundbreaking solutions that could transform the lives of millions.

At Atomwise, we're committed to using AI to accelerate drug discovery and improve patient outcomes. This appointment and our strategy are a testament to our dedication to creating #FirstInClass and #BestInClass medicines for patients. 

Stay tuned for more updates as we continue to push the boundaries of what's possible in medicine and science! 

#AI #DrugDiscovery #HealthcareInnovation #TYK2Inhibition #Atomwise

https://lnkd.in/ecSizR_6

Tomorrow is the Day! Greg Friedland, Sr. Principal Software Engineer at @Atomwise will be presenting at the upcoming ACS Fall Symposium "Taking a Deep Dive into the Chemical Space” on August 16th. His presentation is titled "Complementary Methods for Exploring Ultra-large Combinatorial Synthesis Libraries in Fragment-space," work of which was done in collaboration with his fantastic co-authors Saulo de Oliveira, Aryan Pedawi, Adrian Morrison, and Henry van den Bedem, + many more esteemed colleagues at Atomwise. Make sure you catch Greg and the other speakers in this symposium as they "Deep Dive into the Chemical Space!"

#AI  #drugdiscovery

https://hubs.la/Q01_3Kk00



COM:ATOMWISE

Atomwise

locale

market

industry

website

crunchbase

linkedin

founding date

peer of

competitor of

Metrics